|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, GG-GG (PNPLA3-IL28B) is considered a high-risk signature for higher degree of fibrosis.<b>Conclusion:</b> IL28B rs8099917 and PNPLA3 rs738409 introduce genetic signature to identify patients at higher risk for CHC susceptibility and fibrosis progression in CHC G4.
|
31793339 |
2019 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409[G] allele is a reliable predictor for steatosis and fibrosis in CHC.
|
31642820 |
2019 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A recent meta-analysis revealed that the genotype PNPLA3 rs738409 GG is associated with a higher risk of hepatic steatosis (HS) in Caucasian patients with chronic hepatitis C (CHC).
|
28797039 |
2017 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 genetic polymorphism at rs738409 was verified in 1077 biopsy-proven CHC patients.
|
25457210 |
2015 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3/Adiponutrin rs738409 C/G single nucleotide polymorphism is associated with the severity of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease, as well as the severity of steatosis and fibrosis in patients with chronic hepatitis C (CHC).
|
25801076 |
2015 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genetic variant in adiponutrin (PNPLA3) gene, rs738409 C/G, is associated with steatosis, severity, and progression of liver fibrosis in CHC patients, and predicts treatment outcome in difficult-to-cure HCV-infected patients with advanced fibrosis.
|
26389885 |
2015 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We observed an interaction between homozygosity for the PNPLA3 I148M variant and age at infection in determining fibrosis progression in CHC patients.
|
25171251 |
2014 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC).
|
22530607 |
2012 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Modulation of serum adiponectin might be involved in mediating the susceptibility to steatosis, NASH, and hepatocellular carcinoma in carriers of the 148 M PNPLA3 variant without CHC, with potential therapeutic implications.
|
22898488 |
2012 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs738409 PNPLA3 genotype influences steatosis development in CHC and is independently associated with cirrhosis and other steatosis-related clinical outcomes, such as lack of response to antiviral treatment and possibly HCC.
|
21319195 |
2011 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 (rs738409 C>G) polymorphism favors steatosis and fibrosis progression in CHC.
|
21488075 |
2011 |